Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 block...
Q2 2026
Aug 14, 2026
Q1 2026
May 7, 2026
FY 2025
Mar 5, 2026
Q4 2025
Q3 2025
Nov 6, 2025